alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 7,051–7,075 of 27,380 studies, newest first · page 283 of 1096.

December 2023 25

  1. 2023-12-24

    Correlations between Dementia and Loneliness

    ✓ Peer-reviewed Risk factors International journal of molecular sciences

    Key finding: According to the first one, not sufficiently engaging in social or cognitive activities results in brain atrophy. +1 more finding

    Full summary, score breakdown and related studies → Original source

  2. 2023-12-24

    Amelioration of Amyloid-β Induced Alzheimer's Disease by Bacopa monnieri through Modulation of Mitochondrial Dysfunction and GSK-3β/Wnt/β-Catenin Signaling

    ✓ Peer-reviewed Tau biomarkers Molecular nutrition & food research

    Key finding: Alzheimer's disease (AD) is the most prevalent dementia, affecting a large number of populations. +3 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2023-12-22

    Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia (Amsterdam, Netherlands)

    Key finding: Higher concentrations of plasma p-tau217, p-tau181, and NfL were correlated to higher decline speed of Mini-Mental State Examination score, and higher risk of incident dementia and AD. +2 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2023-12-21

    The autophagy of stress granules

    ✓ Peer-reviewed Disease mechanisms FEBS letters

    Key finding: Mutations and disease-associated variants implicated in amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and frontotemporal lobar dementia compromise autophagy, whilst autophagy-inhibiting drugs or knockdown of essential autophagy proteins result in the persistence of SGs.

    Full summary, score breakdown and related studies → Original source

  5. 2023-12-21

    Magnesium-L-threonate treats Alzheimer's disease by modulating the microbiota-gut-brain axis

    ✓ Peer-reviewed Disease mechanisms Neural regeneration research

    Key finding: We also found that differential metabolites in the magnesium-L-threonate-regulated serum were enriched in various pathways associated with neurodegenerative diseases. +2 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2023-12-21

    Impact of fee-revision policy for gastrostomy on its implementation among older adults with dementia in Japan

    ✓ Peer-reviewed Health systems and care delivery Public health

    Key finding: The number of PEG procedures decreased significantly only in the month wherein the third intervention was introduced (broad definition: IRR = 0.11, CI = 0.03-0.49; narrow definition: IRR = 0.15, CI = 0.03-0.75). +1 more finding

    Full summary, score breakdown and related studies → Original source

  7. 2023-12-21

    Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma

    ✓ Peer-reviewed TREM2 and immune genetics Cell

    Key finding: Empirical in vivo genomic technologies that capture cellular dynamics are currently lacking. +3 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2023-12-20

    Discrimination of Frailty Phenotype by KinectTM-Based Stepping Parameters

    ✓ Peer-reviewed Cognitive tests and assessment JAR life

    Key finding: The number (%) of participants with frailty were 51 (9.1). +2 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2023-12-20

    High-Performance Plasma Biomarker Panel for Alzheimer's Disease Screening Using a Femtomolar-Level Label-Free Biosensing System

    ✓ Peer-reviewed Biomarkers ACS nano

    Key finding: In addition, the panel demonstrated an advantage in the individual-based stage assessment compared with that of the Mini-Mental State Examination/Montreal Cognitive Assessment and nuclear magnetic resonance imaging.

    Full summary, score breakdown and related studies → Original source

  10. 2023-12-19

    Longitudinal trajectories of cognitive reserve in hypometabolic subtypes of Alzheimer's disease

    ✓ Peer-reviewed Risk factors Neurobiology of aging

    Key finding: Previous studies have demonstrated resilience to AD-related neuropathology in a form of cognitive reserve (CR). +3 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2023-12-19

    Microglial APOE4: more is less and less is more

    ✓ Peer-reviewed Genetics Molecular neurodegeneration

    Key finding: Apolipoprotein E (APOE) is the single greatest genetic risk factor for late onset Alzheimer's disease (AD). +2 more findings

    Full summary, score breakdown and related studies → Original source

  12. 2023-12-19

    Advanced structural brain aging in preclinical autosomal dominant Alzheimer disease

    ✓ Peer-reviewed Biomarkers Molecular neurodegeneration

    Key finding: We extend prior work using BAG from sporadic AD to ADAD, noting consistent results. +4 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2023-12-19

    Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals

    ✓ Peer-reviewed Biomarkers Annals of neurology

    Key finding: Relationships between CSF biomarkers but not imaging biomarkers varied by racialized groups.

    Full summary, score breakdown and related studies → Original source

  14. 2023-12-18

    PM2.5 pollution in Texas: a geospatial analysis of health impact functions

    ✓ Peer-reviewed Risk factors Frontiers in public health

    Key finding: This study found that air pollution poses significant risks to the health of Texans, despite the fact that pollution levels across most of the state comply with the EPA standard for PM2.5 pollution of 12 μg/m3.

    Full summary, score breakdown and related studies → Original source

  15. 2023-12-15

    The Function of Sleep and the Treatment of Primary Insomnia

    ✓ Peer-reviewed Risk factors Deutsches Arzteblatt international

    Key finding: The important functions of sleep include cleaning processes such as the elimination of metabolic products, e.g., amyloid, via the glymphatic system; consolidation of memory; and anabolic regulation of metabolism. +4 more findings

    Full summary, score breakdown and related studies → Original source

  16. 2023-12-15

    VEGF controls microglial phagocytic response to amyloid-β

    ✓ Peer-reviewed TREM2 and immune genetics Frontiers in cellular neuroscience

    Key finding: Compelling evidence now indicate that Aβ oligomers (Aβo) are the most toxic forms responsible for neuronal and synaptic alterations. +2 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2023-12-15

    Trends in Incident Dementia Diagnosis Before and After Medicare Risk Adjustment

    ✓ Peer-reviewed Health systems and care delivery JAMA Network Open

    Key finding: This cohort study examines rates of new diagnosis of Alzheimer disease and related dementias among beneficiaries of Medicare Advantage plans vs traditional Medicare from 2016 through 2020.

    Full summary, score breakdown and related studies → Original source

  18. 2023-12-14

    baz-2 enhances systemic proteostasis in vivo by regulating acetylcholine metabolism

    ✓ Peer-reviewed Disease mechanisms Cell reports

    Key finding: Neurodegenerative disorders, such as Alzheimer's disease (AD) or Huntington's disease (HD), are linked to protein aggregate neurotoxicity. +4 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2023-12-14

    Efficacy assessment of an active tau immunotherapy in Alzheimer's disease patients with amyloid and tau pathology: a post hoc analysis of the "ADAMANT" randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial

    ✓ Peer-reviewed Clinical trials EBioMedicine

    Key finding: The prediction model achieved PPV of 97.7% for amyloid, 96.2% for tau. 119 participants in the full analysis set (70 treatment and 49 placebo) were classified as A+T+. +4 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2023-12-14

    The Latest Advances in the Diagnosis and Treatment of Dementia

    ✓ Peer-reviewed Treatments Cureus

    Key finding: Furthermore, personalized treatments have also gained significant attention in dementia treatment.

    Full summary, score breakdown and related studies → Original source

  21. 2023-12-14

    Lecanemab: More Questions Than Answers!

    ✓ Peer-reviewed Treatments Clinical drug investigation

    Key finding: Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer's disease drug targeting amyloid beta that has shown statistically significant cognitive benefits in phase III trials.

    Full summary, score breakdown and related studies → Original source

  22. 2023-12-14

    Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessment

    ✓ Peer-reviewed Biomarkers Frontiers in neurology

    Key finding: High diagnostic sensitivity and negative predictive value (NPV) for Aβ-PET positivity were observed, consistent with the clinical performance of other plasma LC-MS/MS assays, but with greater separation between Aβ42/40 values for individuals with positive vs negative Aβ-PET results. +2 more findings

    Full summary, score breakdown and related studies → Original source

  23. 2023-12-14

    Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases

    ✓ Peer-reviewed Drug development Tissue barriers

    Key finding: We find that IRAs can cross the BBB by two separate processes; one that is fast and one that is slow.

    Full summary, score breakdown and related studies → Original source

  24. 2023-12-14

    Amyloid Beta Oligomers Activate Death Receptors and Mitochondria-Mediated Apoptotic Pathways in Cerebral Vascular Smooth Muscle Cells; Protective Effects of Carbonic Anhydrase Inhibitors

    ✓ Peer-reviewed Treatments Cells

    Key finding: We have previously shown that, in brain endothelial cells (ECs), vasculotropic Aβ species induce apoptosis through death receptors (DRs) DR4 and DR5 and mitochondria-mediated mechanisms, while FDA-approved carbonic anhydrase inhibitors (CAIs) prevent mitochondria-mediated EC apoptosis in vitro and in vivo.

    Full summary, score breakdown and related studies → Original source

  25. 2023-12-14

    Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease

    ✓ Peer-reviewed Treatments The Annals of pharmacotherapy

    Key finding: Lecanemab is a humanized monoclonal antibody that is selective for soluble amyloid-beta (Aβ) aggregates.

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →